← Back to Search

LFA-1/ICAM-1 Antagonist

Lifitegrast for Dry Eye Syndrome

Phase 4
Waitlist Available
Led By Frank A Bucci, Jr., MD
Research Sponsored by Bucci Laser Vision Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Positive for MMP-9 bilaterally as assessed by the Inflammadry assay
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights

Study Summary

This trial will test whether Xiidra can reduce inflammation of the eye surface in both pre- and post-operative cataract patients.

Eligible Conditions
  • Dry Eye Syndrome

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Compare the conversion rates of bilateral positive MMP-9 to negative in pre-cataract and post-cataract patients receiving treatment with Xiidra versus no Xiidra

Trial Design

2Treatment groups
Active Control
Group I: ControlActive Control1 Intervention
No treatment
Group II: LifitegrastActive Control1 Intervention
One drop of Lifitegrast Ophthalmic Solution 5% will be instilled into each eye twice daily (approximately 12 hours apart) using a single-use conainer.

Find a Location

Who is running the clinical trial?

Bucci Laser Vision InstituteLead Sponsor
6 Previous Clinical Trials
264 Total Patients Enrolled
Frank A Bucci, Jr., MDPrincipal InvestigatorBucci Laser Vision
5 Previous Clinical Trials
513 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Ocular Inflammation in Cataract Patients and Response to Treatment With Xiidra
2021. "Ocular Inflammation in Cataract Patients and Response to Treatment With Xiidra". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04120987.
~0 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top